Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Similin 30** is Gan & Lee's premixed recombinant human insulin product for diabetes mellitus. It contains 30% soluble human insulin for relatively rapid prandial insulin activity and 70% protamine human insulin for intermediate-duration basal insulin activity. The biphasic formulation activates the insulin receptor to promote peripheral glucose uptake and suppress hepatic glucose output; it is supplied as a 100 units/mL injectable suspension for subcutaneous use and is approved in China for people with diabetes, including adults with type 1 or type 2 diabetes. ([ganleediabetes.com](https://www.ganleediabetes.com/insulin/12.html))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mixed protamine human insulin injection 30R.